Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
出版年份 2023 全文链接
标题
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
作者
关键词
-
出版物
LANCET
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2023-11-03
DOI
10.1016/s0140-6736(23)02302-4
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Long-Term Outcomes in IgA Nephropathy
- (2023) David Pitcher et al. Clinical Journal of the American Society of Nephrology
- Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
- (2023) Hiddo J L Heerspink et al. LANCET
- A meta-analysis of GFR slope as a surrogate endpoint for kidney failure
- (2023) Lesley A. Inker et al. NATURE MEDICINE
- IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study
- (2023) Jonathan Barratt et al. Kidney International Reports
- Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
- (2023) Richard Lafayette et al. LANCET
- Targeting the Endothelin A Receptor in IgA Nephropathy
- (2023) Donald E. Kohan et al. Kidney International Reports
- A Shared Nephroprotective Mechanism for Renin-Angiotensin-System Inhibitors, Sodium-Glucose Co-Transporter 2 Inhibitors, and Vasopressin Receptor Antagonists: Immunology Meets Hemodynamics
- (2022) Giovanna Capolongo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy
- (2022) Jicheng Lv et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
- (2022) Jonathan Barratt et al. KIDNEY INTERNATIONAL
- Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis
- (2021) Lesley A. Inker et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
- (2021) David C. Wheeler et al. KIDNEY INTERNATIONAL
- Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
- (2021) Brad H Rovin et al. LANCET
- An Update on the Current State of Management and Clinical Trials for IgA Nephropathy
- (2021) Chee Kay Cheung et al. Journal of Clinical Medicine
- KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
- (2021) Brad H. Rovin et al. KIDNEY INTERNATIONAL
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials
- (2019) Lesley A. Inker et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Coping with missing data in phase III pivotal registration trials: Tolvaptan in subjects with kidney disease, a case study
- (2017) John Ouyang et al. PHARMACEUTICAL STATISTICS
- A New Equation to Estimate Glomerular Filtration Rate
- (2013) Andrew S. Levey et al. ANNALS OF INTERNAL MEDICINE
- IgA Nephropathy
- (2013) Robert J. Wyatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Pathophysiology of IgA Nephropathy
- (2011) H. Suzuki et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Long-term study of mycophenolate mofetil treatment in IgA nephropathy
- (2009) Sydney C.W. Tang et al. KIDNEY INTERNATIONAL
- Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy
- (2009) C. Manno et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started